查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433686

胜肽/寡核苷酸 CDMO 市場規模、佔有率、趨勢分析報告：按產品類型、服務類型、最終用途、地區和細分市場預測，2024-2030 年

Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Product (Peptides, Oligonucleotides), By Service Type, By End Use (Pharmaceutical Companies, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10個工作天內

價格

胜肽/寡核苷酸 CDMO 市場成長與趨勢：

Grand View Research 的最新報告顯示，到 2030 年，全球胜肽和寡核苷酸 CDMO 市場預計將達到 56.7 億美元。

2024年至2030年的複合年成長率為12.5%。人們日益認知到胜肽和寡核苷酸作為各種疾病的有價值的治療劑，正在推動對 CDMO 服務的需求。此外，胜肽和寡核苷酸療法的管道不斷增加以及 CDMO 在該領域的滲透率不斷提高也是推動市場成長的因素。

市場分散，多家公司擁有相似的技術力和加工能力。這些公司提供與胜肽和寡核苷酸開發、資料解釋、樣本分析和臨床試驗支援相關的各種服務。該市場的特點是品質保證、技術進步、監管合規以及提供高價值和多樣化服務的能力等因素驅動的激烈競爭。

領先公司增加對基於胜肽和寡核苷酸的療法的開發和製造的投資是支持市場成長的突出因素之一。例如，2023 年 9 月，CordenPharma 宣布擴大商業胜肽產能，新增 CordenPharma Colorado，目前是全球最大的固胜肽合成 (SPPS) 製造廠。此外，2023年9月，CombiGene選擇AmbioPharm作為其基於胜肽的疼痛計劃COZY01的CDMO合作夥伴，該計畫也涉及Zyneyro。

COVID-19 大流行對市場產生了中等影響。 COVID-19 大流行的早期階段對臨床試驗產生了重大影響，導致旅行限制、供應鏈中斷和臨床試驗受挫。儘管如此，人們越來越重視抗病毒胜肽和 mRNA 疫苗的快速發展。此外，生物製藥公司之間的合作和聯盟也顯著增加，以促進基於胜肽的治療藥物的生產。

胜肽/寡核苷酸 CDMO 市場報告亮點

  • 此細分市場的推動因素是對基於胜肽的療法的需求不斷成長以及涉及胜肽使用的臨床試驗數量的增加。
  • 依服務類型分類，契約製造業務佔比最大，2023年將達65.0%。該細分市場的巨大市場佔有率主要歸因於製造外包成本效益驅動的製造外包服務需求不斷成長。
  • 由於越來越多的生物製藥公司專注於胜肽藥物的研發，預計生物製藥公司在分析期間的複合年成長率為13.0%。
  • 預計亞太地區在預測期內複合年成長率最高，達 13.4%。這一顯著成長主要是由於西方製藥公司越來越傾向將製造業務外包給中國和印度等新興國家。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章胜肽寡核苷酸CDMO市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 胜肽/寡核苷酸CDMO市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第4章胜肽/寡核苷酸 CDMO 市場：產品估算/趨勢分析

  • 胜肽/寡核苷酸 CDMO 市場，副產品：細分儀表板
  • 胜肽/寡核苷酸CDMO市場，依產品：波動分析

第5章胜肽/寡核苷酸CDMO市場：服務類型估算/趨勢分析

  • 按服務類型分類的胜肽核苷酸 CDMO 市場：細分儀表板
  • 按服務類型分類的胜肽/寡核苷酸 CDMO 市場：波動分析

第6章胜肽/寡核苷酸 CDMO 市場：最終用途估計和趨勢分析

  • 按最終用途分類的胜肽核苷酸 CDMO 市場：細分儀表板
  • 胜肽/寡核苷酸 CDMO 市場，依最終用途：波動分析

第7章胜肽/寡核苷酸CDMO市場：區域估算和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 市場參與企業分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 2023 年公司市場佔有率分析
  • 公司簡介
    • PolyPeptide Group
    • STA Pharmaceutical Co. Ltd.
    • Bachem
    • Creative Peptides
    • Aurigene Pharmaceutical Services Ltd
    • Merck KGaA
    • EUROAPI
    • Curia Global, Inc.
    • CordenPharm
    • Sylentis, SA
Product Code: GVR-4-68040-182-4

Peptide And Oligonucleotide CDMO Market Growth & Trends:

The global peptide and oligonucleotide CDMO market is expected to reach USD 5.67 billion by 2030, according to a new report by Grand View Research, Inc. , registering a CAGR of 12.5% from 2024 to 2030. The growing recognition of peptides and oligonucleotides as valuable therapeutic agents for various diseases is fueling the demand for CDMO services. Moreover, the increasing pipeline of peptides and oligonucleotide therapeutics and the growing penetration of CDMOs in the field are a few of the factors driving the growth of the market.

The market is fragmented, with several players having similar technological and processing capabilities. These companies offer various services related to peptide and oligonucleotide development, data interpretation, sample analysis, and clinical trial support. The market is characterized by fierce competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.

The growing investment by major companies in the development and manufacturing of peptides and oligonucleotide-based therapeutics is one of the prominent factors supporting the growth of the market. For instance, in September 2023, CordenPharma announced the expansion of its commercial peptide production capabilities through the enhancement of facilities at CordenPharma Colorado, which now stands as the world's largest Solid-Phase Peptide Synthesis (SPPS) manufacturing facility. Additionally, in September 2023, CombiGene selected AmbioPharm as the CDMO partner for their peptide-based pain project, COZY01, which also involves Zyneyro.

The COVID-19 pandemic moderately impacted the market. The early stages of the COVID-19 pandemic had a notable impact on clinical trials, as a result of travel restrictions, disruptions in the supply chain, and setbacks in clinical trials. Nonetheless, it also presented prospects, notably the heightened emphasis on antiviral peptides and the swift creation of mRNA vaccines. Furthermore, there has been a substantial increase in collaborations and partnerships across biopharmaceutical companies with an aim to boost the production of peptide-based therapeutics.

Peptide And Oligonucleotide CDMO Market Report Highlights:

  • The peptides segment accounted for the largest share of 66.3% in 2023.The segment is driven by the growing demand for peptide-based therapeutics and the rise in the number of clinical trials involving the use of peptides.
  • Based on the service type, the contract manufacturing segment accounted for the largest share of 65.0% in 2023. The substantial market share in this segment primarily results from the growing demand for outsourced manufacturing services, driven by the cost-effectiveness of outsourced manufacturing.
  • Biopharmaceutical companies are anticipated to witness the highest CAGR of 13.0% across the analysis timeframe due to the increasing number of biopharmaceutical companies focusing on research and development of peptide-based drugs.
  • Asia Pacific is anticipated to witness the highest CAGR of 13.4% during the forecast time frame. The substantial growth is primarily attributed to the rising trend of Western pharmaceutical companies outsourcing their manufacturing operations to emerging economies like China and India.

Table of contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Product
    • 1.1.3. Service Type
    • 1.1.4. End Use
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Peptide and Oligonucleotide CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing therapeutic applications of peptides and oligonucleotides
      • 3.2.1.2. Advances in peptide synthesis, delivery methods, and gene-editing technologies have expanded the possibilities for developing innovative therapies
      • 3.2.1.3. Growing research and development investments
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Complexities associated with clinical trial studies
      • 3.2.2.2. Challenges related to quality control
  • 3.3. Peptide and Oligonucleotide CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Peptide and Oligonucleotide CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Peptide and Oligonucleotide CDMO Market, By Product: Segment Dashboard
  • 4.2. Peptide and Oligonucleotide CDMO Market, By Product: Movement Analysis
  • 4.3. Peptide and Oligonucleotide CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
    • 4.3.1. Peptides
      • 4.3.1.1. Peptides Clinical Phase Outsourcing Services Market, 2018 to 2030, (USD Million)
    • 4.3.2. Oligonucleotides
      • 4.3.2.1. Oligonucleotides Clinical Phase Outsourcing Services Market, 2018 to 2030, (USD Million)

Chapter 5. Peptide and Oligonucleotide CDMO Market: Service Type Estimates & Trend Analysis

  • 5.1. Peptide and Oligonucleotide CDMO Market, By Service Type: Segment Dashboard
  • 5.2. Peptide and Oligonucleotide CDMO Market, By Service Type: Movement Analysis
  • 5.3. Peptide and Oligonucleotide CDMO Market Estimates & Forecasts, By Service Type, 2018 - 2030
    • 5.3.1. Contract Development
      • 5.3.1.1. Contract Development Peptide and Oligonucleotide CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2. Contract Manufacturing
      • 5.3.2.1. Contract Manufacturing Peptide and Oligonucleotide CDMO Market, 2018 to 2030, (USD Million)

Chapter 6. Peptide and Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Peptide and Oligonucleotide CDMO Market, By End Use: Segment Dashboard
  • 6.2. Peptide and Oligonucleotide CDMO Market, By End Use: Movement Analysis
  • 6.3. Peptide and Oligonucleotide CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
    • 6.3.1. Pharmaceutical Companies
      • 6.3.1.1. Pharmaceutical Companies Peptide and Oligonucleotide CDMO Market 2018 to 2030 (USD Million)
    • 6.3.2. Biopharmaceutical Companies
      • 6.3.2.1. Biopharmaceutical Companies Peptide and Oligonucleotide CDMO Market 2018 to 2030 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Others Peptide and Oligonucleotide CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Peptide and Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. PolyPeptide Group
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Service Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. STA Pharmaceutical Co. Ltd.
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Service Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. Bachem
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Service Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Creative Peptides
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Service Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. Aurigene Pharmaceutical Services Ltd
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Service Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Merck KGaA
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Service Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. EUROAPI
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Service Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. Curia Global, Inc.
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Service Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. CordenPharm
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Service Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. Sylentis, S.A.
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Service Benchmarking
      • 8.2.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 5 North America Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 6 North America Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 7 U.S. Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 Canada Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 12 Canada Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Europe Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 14 Europe Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 15 Europe Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 16 Europe Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 17 U.K. Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 18 U.K. Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 19 U.K. Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Germany Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 22 Germany Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 France Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 24 France Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 25 France Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Italy Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 27 Italy Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 28 Italy Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Spain Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 30 Spain Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 31 Spain Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Denmark Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 34 Denmark Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Sweden Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 37 Sweden Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Norway Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 39 Norway Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 40 Norway Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 China Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 46 China Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 47 China Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Japan Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 50 Japan Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 India Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 52 India Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 53 India Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Australia Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 55 Australia Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 56 Australia Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 South Korea Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 59 South Korea Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 Thailand Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 61 Thailand Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 62 Thailand Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 Latin America Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 64 Latin America Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 65 Latin America Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Latin America Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Brazil Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 68 Brazil Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 69 Brazil Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 70 Mexico Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 71 Mexico Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 72 Mexico Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Argentina Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 75 Argentina Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa Peptide and Oligonucleotide CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 79 Middle East and Africa Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 80 South Africa Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 82 South Africa Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 UAE Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 87 UAE Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 88 UAE Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Peptide and Oligonucleotide CDMO market, by Service Type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Peptide and Oligonucleotide CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Peptide and Oligonucleotide CDMO market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modelling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Peptide and Oligonucleotide CDMO market segmentation
  • Fig. 18 Parent market outlook (2023)
  • Fig. 19 Related/ancillary market outlook (2023)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Market restraint relevance analysis (Current & future impact)
  • Fig. 22 Porter's five forces analysis
  • Fig. 23 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 24 Peptide and Oligonucleotide CDMO Market Product outlook: Segment dashboard
  • Fig. 25 Peptide and Oligonucleotide CDMO :Product movement analysis
  • Fig. 26 Peptides market, 2018 - 2030 (USD Million)
  • Fig. 27 Oligonucleotides market, 2018 - 2030 (USD Million)
  • Fig. 28 Peptide and Oligonucleotide CDMO Market Service Type outlook: Segment dashboard
  • Fig. 29 Peptide and Oligonucleotide CDMO : Service Type type movement analysis
  • Fig. 30 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 31 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 32 Peptide and Oligonucleotide CDMO market End Use outlook: Segment dashboard
  • Fig. 33 Peptide and Oligonucleotide CDMO market: End Use movement analysis
  • Fig. 34 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 35 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 36 Others market, 2018 - 2030 (USD Million)
  • Fig. 37 Regional marketplace: Segment dashboard
  • Fig. 38 Regional outlook, 2023 & 2030
  • Fig. 39 North America market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 41 Canada market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany market, 2018 - 2030 (USD Million)
  • Fig. 44 UK market, 2018 - 2030 (USD Million)
  • Fig. 45 France market, 2018 - 2030 (USD Million)
  • Fig. 46 Italy market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark market, 2018 - 2030(USD Million)
  • Fig. 49 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 50 Norway market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 52 China market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan market, 2018 - 2030 (USD Million)
  • Fig. 54 India market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 57 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 58 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 59 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 60 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 61 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 62 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 63 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 64 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 65 UAE market, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait market, 2018 - 2030 (USD Million)